Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Growth in Short Interest

Abivax SA Sponsored ADR (NASDAQ:ABVX) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 2,908,643 shares, a growth of 25.0% from the December 15th total of 2,327,324 shares. Approximately 3.7% of the shares of the stock are sold short. Based on an average trading volume of 1,741,255 shares, the short-interest ratio is currently 1.7 days. Based on an average trading volume of 1,741,255 shares, the short-interest ratio is currently 1.7 days. Approximately 3.7% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ABVX. Citigroup reaffirmed a “market outperform” rating on shares of Abivax in a research note on Thursday, January 8th. Morgan Stanley upped their price objective on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a report on Wednesday, October 8th. Oppenheimer set a $131.00 price target on shares of Abivax in a research report on Thursday, January 8th. Finally, Truist Financial set a $140.00 price objective on shares of Abivax in a research report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $135.08.

Abivax Stock Performance

Abivax stock opened at $117.10 on Friday. Abivax has a fifty-two week low of $4.77 and a fifty-two week high of $148.83. The firm’s 50 day simple moving average is $121.98 and its 200-day simple moving average is $89.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. The company has a market cap of $9.13 billion, a P/E ratio of -28.01 and a beta of 0.68.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The business had revenue of ($4.92) million for the quarter. As a group, equities research analysts predict that Abivax will post -2.83 EPS for the current year.

Hedge Funds Weigh In On Abivax

A number of large investors have recently made changes to their positions in ABVX. EverSource Wealth Advisors LLC lifted its position in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares in the last quarter. First Horizon Corp acquired a new position in Abivax in the 3rd quarter valued at approximately $36,000. Union Bancaire Privee UBP SA purchased a new stake in Abivax in the 4th quarter worth approximately $67,000. Hantz Financial Services Inc. purchased a new position in shares of Abivax during the 3rd quarter valued at $52,000. Finally, Gordian Capital Singapore Pte Ltd acquired a new position in shares of Abivax in the third quarter worth $76,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.